Boya Bio-pharmaceutical Group Co Ltd operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Boya Bio-pharmaceutical Group Co Ltd with three other
companies in this sector in CHINA :
Shanghai Raas Blood Products Company Limited
sales of 2.58 billion Chinese Renmimbi [US$362.65 million]
of which 100%
was Blood products production and sales),
Beijing Tiantan Biologic.
(3.28 billion Chinese Renmimbi [US$460.41 million]
of which 100%
was Blood products), and
Tonghua Dongbao Medicines Company Limited
(2.78 billion Chinese Renmimbi [US$389.39 million]
of which 95%
Boya Bio-pharmaceutical Group Co Ltd reported sales of 2.91 billion Chinese Renmimbi (US$408.07 million)
December of 2019.
increase of 18.7%
versus 2018, when the company's sales were 2.45 billion Chinese Renmimbi.
Sales at Boya Bio-pharmaceutical Group Co Ltd have increased during each of the previous five years
(and since 2014, sales have increased a total of 564%).
Sales of Other Mainbusiness saw an increase
that was more than double the company's growth rate: sales were up
313.3% in 2019, from
5.47 million Chinese Renmimbi to 22.60 million Chinese Renmimbi.
Boya Bio-pharmaceutical Group Co Ltd also saw significant increases in sales in
Bio-Pharmaceuticals (up 28.6% to 903.05 million Chinese Renmimbi)